For HER-2+ breast cancer, data have shown that the expression of HER-2 CAR in NK cells from healthy donors and breast cancer patients can effectively enhance its anti-tumor function against various HER-2-expressing cancer cells, and compared with MHC class I expression is irrelevant. Here, ERBB2 is linked to neoplasm.